Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab

Satish Chaudhary; Reetesh Sharma; Saumya Gupta; Sita Paikra; Mohit Gupta; Bal K Upadhyay; Alok Sharma; Rajiv K Sethia

doi:10.4103/ijn.ijn_345_22

Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab

Indian J Nephrol. 2024 Mar-Apr;34(2):191-194. doi: 10.4103/ijn.ijn_345_22. Epub 2023 Apr 4.

Authors

Satish Chaudhary¹, Reetesh Sharma¹, Saumya Gupta¹, Sita Paikra¹, Mohit Gupta¹, Bal K Upadhyay¹, Alok Sharma², Rajiv K Sethia¹

Affiliations

¹ Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India.
² Nephrology and Kidney Transplant Medicine, Dr. Lalpathlabs National Reference Laboratories, New Delhi, India.

Abstract

Posttransplant thrombotic microangiopathy (PT-TMA) can be caused by calcineurin inhibitors (CNIs), ischemic injury, infections, or antibody-mediated rejection (ABMR). Delayed recognition can result in allograft loss. We describe the first reported case of successful reversal of refractory PT-TMA with eculizumab in India. It highlights the importance of prompt diagnosis and benefit from an early initiation of eculizumab therapy in refractory cases.

Keywords: Eculizumab; refractory posttransplant TMA; thrombotic microangiopathy.

Publication types

Case Reports

Grants and funding

Financial support and sponsorship